xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

410

International consensus statement on rhinosinusitis

VAS, endoscopy scores Mometasone and clarithromycin had

comparable effect on CRSsNP.

SNOT-20 and CT scores were significantly improved in both groups.

Clinical effectiveness was higher in the

combination group than monotherapy group at 12weeks.

Azithromycin showed no benefit over placebo.

patient response scale,

nasal endoscopy, SCT,

and IL-8 level in lavage fluid.

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Videler 1111 2011 2 RCT CRSsNP (n = 29) and CRSwNP (n = 31);

Improved SNOT-20,

symptom score, CT score, nasal examination

endoscopy, PNIF, Sniffin’

Sticks smell tests, middle meatus culture

scale, peak inspiratory flow, SCT, endoscopic score, olfaction, nasal lavage assays

SNOT-20, subjective

SNOT-22,VAS, SF36,

SNOT-20, patient response

Roxithromycin 150 mg/d (N = 29) vs control (N = 35) for 12 weeks

Clarithromycin 200 mg daily +

Mometasone furoate 200 μ gdaily (n = 21)

1. Medical group (n = 30):

S-carboxymethylcysteine daily (n = 213)

vs Clarithromycin 250 mg daily (n = 22) for 12 weeks

azithromycin 500 mg daily for 3 days at week 1, then weekly for 11 weeks.2. Placebo (n = 30).

Majima 1113 2012 3 Cohort study Clarithromycin 200 mg daily (n = 212)

Zeng 1072 2011 2 RCT CRSsNP without ESS

Wallwork 1110 2006 2 RCT CRSsNP without ESS

TABLE IX-31 (Continued)